| Ren, Hong |
NCT05771402: A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B) |
|
|
| Not yet recruiting | 4 | 120 | RoW | Anti-PD-1 antibody, NAs, ETV/TDF/TAF, Peg-IFNα | The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Southwest Medical University, Guizhou Provincial People's Hospital | Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNα | 12/23 | 12/23 | | |
NCT05769816: A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A) |
|
|
| Not yet recruiting | 4 | 120 | RoW | Anti-PD-1 antibody, NAs, ETV/TDF/TAF | The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Southwest Medical University, Guizhou Provincial People's Hospital | Chronic Hepatitis b, Anti-PD-1 Antibody | 12/25 | 12/25 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
NCT05760703: Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B |
|
|
| Terminated | 2 | 9 | RoW | STSG-0002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Sanuo Jiayi Biotechnology Co. LTD | Chronic Hepatitis b | 12/23 | 12/23 | | |
NCT05760781: To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B |
|
|
| Terminated | 2 | 9 | RoW | STSG-0002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Sanuo Jiayi Biotechnology Co. LTD | Chronic Hepatitis b | 12/23 | 12/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT04445194: Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine |
|
|
| Active, not recruiting | 1 | 50 | RoW | Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine (CHO cells) high-dose group, Recombinant new coronavirus vaccine (CHO cells) placebo group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., The Second Affiliated Hospital of Chongqing Medical University, Beijing Chao Yang Hospital | Coronavirus | 10/20 | 09/21 | | |
NCT05559242: Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients |
|
|
| Not yet recruiting | 1 | 30 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Liver Dysfunction | 06/23 | 07/23 | | |
NCT05851261: Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects |
|
|
| Completed | 1 | 60 | RoW | PA3670 | Zhejiang Palo Alto Pharmaceuticals, Inc. | Chronic HBV Infection | 10/23 | 12/23 | | |
NCT05043129: Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection |
|
|
| Recruiting | N/A | 200 | RoW | Biological/Vaccine: SARS-COV-2 VACCINE | The Second Affiliated Hospital of Chongqing Medical University | HIV Infections, Covid19 | 03/22 | 09/22 | | |
NCT03108794: A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B |
|
|
| Recruiting | N/A | 200000 | RoW | | Beijing Friendship Hospital, Beijing YouAn Hospital, The First Hospital of Jilin University, Henan Provincial People's Hospital, Beijing Ditan Hospital, First Affiliated Hospital of Xinjiang Medical University, LanZhou University, The Second Affiliated Hospital of Chongqing Medical University, West China Hospital, Taiyuan No.3 Hospital, Hebei Medical University Third Hospital, Shengjing Hospital, Tianjin Third Central Hospital, Peking University First Hospital, Peking Union Medical College Hospital, The Affiliated Hospital Of Southwest Medical University, Shanghai Public Health Clinical Center, Ruijin Hospital, First Affiliated Hospital Xi'an Jiaotong University, Xiangya Hospital of Central South University, Beijing Tiantan Hospital, Wuhan University, The First Affiliated Hospital of Kunming Medical College, The Affiliated Hospital of Xuzhou Medical University, The Affiliated Hospital of Yanbian University, First Affiliated Hospital of Chongqing Medical University, The Fouth Hospital of Qinghai province, Weifang Medical University, Hunan Provincial People's Hospital, The Second Hospital of Hebei Medical University, Xixi Hospital of Hangzhou, General Hospital of Ningxia Medical University, Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Peking University People's Hospital, Nanfang Hospital of Southern Medical University, The Affiliated Hospital Of Guizhou Medical University, Guizhou Provincial People's Hospital, Hainan General Hospital, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Fifth Hospital of Shijiazhuang City, Yan'an University Affiliated Hospital, Infectious Disease Hospital of Wuhai, Logistics University of Chinese People's Armed Police Forces, People's Hospital of Changji Hui Autonomous Prefecture，Xinjiang | Chronic Hepatitis B | 12/22 | 12/25 | | |
| Recruiting | N/A | 2300 | RoW | SARS-COV-2 VACCINE | The Second Affiliated Hospital of Chongqing Medical University | Diseases, Chronic, Covid19, Adverse Reaction to Vaccine | 05/23 | 08/23 | | |
NCT05043272: Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI |
|
|
| Recruiting | N/A | 450 | RoW | SARS-COV-2 VACCINE | The Second Affiliated Hospital of Chongqing Medical University | Covid19, Overweight | 05/22 | 08/22 | | |
NCT05057065: A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB |
|
|
| Recruiting | N/A | 10000 | RoW | | Hong Ren | Hepatitis B, Chronic | 09/22 | 06/23 | | |
| Not yet recruiting | N/A | 400 | RoW | No interventions | The Second Affiliated Hospital of Chongqing Medical University, Eastern Hepatobiliary Surgery Hospital, Nanfang Hospital of Southern Medical University | Focal Liver Lesions | 04/23 | 10/23 | | |
SIMPLE, NCT05007665: Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases |
|
|
| Recruiting | N/A | 2000 | RoW | SARS-COV-2 VACCINE | The Second Affiliated Hospital of Chongqing Medical University | Liver Diseases, Covid19, Adverse Reaction to Vaccine | 06/23 | 12/23 | | |
